Challenges in clinical prostate cancer: role of imaging. - Test2 - elhamkhani - TriplyDB

Challenges in clinical prostate cancer: role of imaging.

Challenges in clinical prostate cancer: role of imaging.

http://www.wikidata.org/entity/Q33945133

about

PSA and beyond: alternative prostate cancer biomarkers Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging Ultrasound Elastography: Review of Techniques and Clinical Applications.A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer.Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patients.Transrectal real-time elastography of the prostate: Normal patterns.Focused ultrasound surgery in oncology: overview and principles.Magnetic resonance microscopy of prostate tissue: How basic science can inform clinical imaging development Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate MRI-Safe Robot for Endorectal Prostate Biopsy.Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients.Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.New agents and techniques for imaging prostate cancer.PET/CT Imaging and Radioimmunotherapy of Prostate Cancer Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.Stromal prostatic sarcoma: a rare tumor with rare clinical and imaging presentation.MRI of the prostate: clinical relevance and emerging applications.Imaging in prostate cancer diagnosis: present role and future perspectives.Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?Interpretation and reporting multiparametric prostate MRI: a primer for residents and novices.Ultrasound Elastography of the Prostate Using an Unconstrained Modulus Reconstruction Technique: A Pilot Clinical Study.PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.Prostate Cancer With Metastatic Lytic Bone Lesions: Positive Bone Scan Post Docetaxel Chemotherapy in the Setting of Clinically Successful Treatment.Quantitative graphical analysis of simultaneous dynamic PET/MRI for assessment of prostate cancer.3D prostate histology image reconstruction: Quantifying the impact of tissue deformation and histology section location 11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer.Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples.Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients.High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.3D prostate histology reconstruction: an evaluation of image-based and fiducial-based algorithms.Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer.Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP).MR Safe Robot, FDA Clearance, Safety and Feasibility Prostate Biopsy Clinical Trial.

P2860

Q26770646-0277C562-28D9-46CF-94D3-30E1A9E21D73 Q28073470-BC2A5BB9-140D-4D3D-83F1-32E17CE01957 Q28535729-B1D35C87-7B87-4B20-BBC0-F79BB40B7B9D Q30358290-F3D100FA-9D2D-46A9-A2E1-B3212EDA10DD Q30406797-99CD4DEA-50F6-4699-8750-D1FBD345C27E Q30417067-6561ABCF-7949-4DB2-8B87-9BEB1BBBCF5D Q30458336-F03DDB15-489B-4F74-B8B2-369BBC219A9E Q30469164-99C2D6DA-0649-4669-9F78-205A9CA2B073 Q34247368-5BD08D3D-F0A0-4249-818E-0E46F36E609E Q34359533-12DE6610-E939-4053-A25A-4EF53001F50D Q34448754-873F3E1F-3BE0-4509-8D91-E50F0FB78710 Q34550344-F795943A-F04B-4474-B61F-5B130DD7F9DB Q34761435-E6A500B8-8002-4074-B14C-ADE231ED7385 Q34995973-660E9989-27C6-4E59-952F-17DB27206AE0 Q35116088-FCEBB510-ED9E-40CD-ACD4-8195CECF678D Q35700730-44FA66D9-4D4C-4F5A-B99F-A8E7EACFE217 Q35911784-4EFB829F-B03C-4993-9AB1-430958E71E34 Q36085426-6F1C8544-66E3-4BC0-8BC3-CF306F3B7C67 Q36125199-49C35E30-885B-4EBE-81C0-1673AD5661E2 Q37091554-00267CC2-2846-422C-BC45-30EDB529844B Q37463428-09200223-3802-4D10-A671-50893A2DCCA1 Q37833011-F0A08323-EA8E-463C-8BA0-BF357C9EE4F5 Q37849513-4520B36D-EAC1-4745-A11F-2499A18FA89F Q38008282-BACCE2C4-BDB7-42AA-BF9C-1FBB2AA57E5C Q38190885-CBB9E92F-F81E-4409-BC9D-0963E3F794B1 Q38666376-8BD00AAA-7A79-4B31-AC8B-CD54AE5552CB Q38939408-C40957D6-D679-4284-BE86-EEDEC6937A64 Q39217780-1AAD0D52-17F1-4966-A960-5D78F9A8E4A4 Q40968344-42EA6BA3-1103-483D-853B-C6C511E6DB16 Q41548893-1BDE4378-E1BA-4E67-96E7-A80A56C73F48 Q41868904-23840306-3B94-485D-9108-556E0A7145D4 Q42371661-7D807061-054B-4B24-BC30-D9FA1DB3A824 Q42379564-FCE61389-6786-401D-AF98-0EB4B3F40E05 Q42716179-D27148F7-D5CB-4B77-9911-3454087EE464 Q43114045-7528094D-3FFE-46E2-9F7B-46F6B2B1071F Q43216601-96313367-F42D-476E-A232-9F4627B28039 Q44241739-78940F7A-38DF-4215-AF66-C342E4E89192 Q45119553-70273D11-666C-456F-9A33-1E55FE513E3C Q46118170-84DDD777-8A92-4A69-BAF9-26FD7BF28FD8 Q47721757-D0229FAD-A404-4693-A220-7F885ECB4FB9

P2860

Challenges in clinical prostate cancer: role of imaging.

http://www.wikidata.org/entity/Q33945133

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Challenges in clinical prostate cancer: role of imaging.

@ast

Challenges in clinical prostate cancer: role of imaging.

@en

type

label

Challenges in clinical prostate cancer: role of imaging.

@ast

Challenges in clinical prostate cancer: role of imaging.

@en

prefLabel

Challenges in clinical prostate cancer: role of imaging.

@ast

Challenges in clinical prostate cancer: role of imaging.

@en

P1433

Q33945133-AE8AC165-A868-4671-B8AC-2152A1B148B1

P1476

Q33945133-5919C412-797C-4826-9598-87075FAF201A

P2093

Q33945133-1F82EA7E-4081-4BEB-BC9A-0BEDFA66B145

Q33945133-32891647-58B1-4F2A-A151-34051DF264F8

Q33945133-36014950-EA80-4EC7-8C26-468B332850D1

Q33945133-E4D4850F-2F22-4CC9-B0DC-4CA9DCC22E77

P2860

Q33945133-0562CCF6-C0E5-4F55-8F2B-F1FE177C6278

Q33945133-091D33F3-7FE4-4ED5-96A1-C6C559399F20

Q33945133-0B46D0E2-17ED-48E4-A534-C8BFA3812ECD

Q33945133-0C23F815-CC7F-4857-B669-2A103A2992F6

Q33945133-0CFEFE05-EC61-4200-A242-0C53BA98F608

Q33945133-0DEEF728-1949-4681-93C1-3631E193A1D8

Q33945133-0F8A91C2-9626-4863-9305-DE852E56DAF7

Q33945133-118C1263-F67F-42EC-BF96-C5995CF01113

Q33945133-13C26A6B-80D4-4561-BDA1-7B6ED734E939

Q33945133-14C05FE3-558B-4AD1-A846-28DAA63C1BA6

P304

Q33945133-BE817518-DFED-4D49-9169-34768386DEA9

P31

Q33945133-0B854842-E477-49F9-9E2B-81E276F45573

P356

Q33945133-045E6374-E5B7-4470-B35F-09D57DDAC5F7

P407

Q33945133-06804EB7-4C48-4C3B-8964-0DC8C45F659E

P433

Q33945133-D48C40E6-317D-4F62-859E-455CFFDF101A

P478

Q33945133-E79D44E2-7B39-4183-9D69-8A2ABDAAF1C0

P577

Q33945133-528C09EE-C282-4F7F-9122-994733283F6D

P698

Q33945133-F2436537-3AC2-438C-A435-6F1EA11B42E9

P932

Q33945133-647F05FC-EFBA-49BC-A647-FF7DF99924DD

P356

P1433

American Journal of Roentgenology

P1476

Challenges in clinical prostate cancer: role of imaging.

@en

P2093

Donald S Coffey

http://www.w3.org/2001/XMLSchema#string

Gary J Kelloff

http://www.w3.org/2001/XMLSchema#string

Peter Choyke

http://www.w3.org/2001/XMLSchema#string

Prostate Cancer Imaging Working Group

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular pathology of prostate cancer

Cancer statistics, 2008

Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils

Emerging ultrasound technologies for early markers of disease.

Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor.

Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.

Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range

A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer.

Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

P304

1455-1470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2214/AJR.09.2579

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

192

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19457806

http://www.w3.org/2001/XMLSchema#string

P932

2893141

http://www.w3.org/2001/XMLSchema#string